International Journal of Obstetric Anesthesia
Volume 16, Issue 1 , Pages 40-49 , January 2007

Use of recombinant activated factor VII in massive obstetric haemorrhage

  • J. Haynes
    • ,
  • M. Laffan
    • ,
  • F. Plaat

      Affiliations

    • Corresponding Author InformationCorrespondence to: Dr. F. Plaat, Department of Anaesthesia, Queen Charlotte’s and Chelsea Hospital, London, W12 0HS, UK. Tel.: +0208 383 3991.

,Accepted 1 July 2006.

References 

  1. Confidential Enquiry into Maternal and Child Health. Why Mothers Die 2000–2002. The 6th Confidential Enquiry into Maternal Deaths in the United Kingdom. London; RCOG Press: 2004.
  2. Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med. 2002;28:S241–S247
  3. Laffan M, O’Connell NM, Perry DJ, Hodgson AJ, O’Shaughnessy D, Smith OP. Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagul Fibrinolysis. 2003;14(Suppl 1):S35–S38
  4. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Med. 2002;28:S248–S255
  5. Novo Nordisk Limited. NovoSeven summary of product characteristics. Version No. 3; N7/IBEC/015/3.
  6. Moscado F, Perez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol. 2001;113:174–176
  7. Brueckner S, Sedmund-Adib B, Malik E, et al. Treatment of a post-partum bleeding complication with recombinant factor VIIa. Blood. 2001;98:80
  8. Zupancic S, Sokolic V, Viskovic T, Sanjug J, Simic M, Kastelan M. Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol. 2002;108:162–163
  9. Sokolic V, Bukovic D, Fures R, et al. Recombinant factor VIIa (rFVIIa) is effective at massive bleeding after caesarean section – a case report. Coll Antropol. 2002;26(Suppl):155–157
  10. Breborowicz G, Sobieszczyk S, Szymankiewicz M. Efficacy of recombinant activated factor VII (rFVIIa, NovoSeven®) in prenatal medicine. Arch Perinat Med. 2002;8:21–27
  11. Sobieszczyk S, Breborowicz G, Markwitz W, Mallinger S, Adamski D, Krusynski Z. Effect of recombinant activated factor VII (rFVIIa: NovoSeven®) in a patient in haemorrhagic shock after obstetrical hysterectomy. Ginekol Pol. 2002;73:230–233
  12. Bouwmeester F, Jonkhoff A, Verheijen R, Van-Geijn H. Successful treatment of life-threatening post-partum haemorrhage with recombinant activated factor VII. Obstet Gynecol. 2003;101:1174–1176
  13. Bielanow T, Sidor M, Maciejewski M, Skrzypek W. Effectiveness of recombinant activated factor VII (NovoSeven®) in a case of severe obstetric complication with coagulopathy. Ginekol Pol. 2003;74:1055–1059
  14. Kretzschmar M, Zahm D, Remmler K, Pfeiffer L, Victor L, Schirrmeister W. Pathophysiological and therapeutic aspects of amniotic fluid embolism (anaphylactoid syndrome of pregnancy): Case report with lethal outcome and overview. Anaesthetist. 2003;52:419–426
  15. Michalska-Krzanowska G, Stasiak-Pikula E, Sajdak R. Recombinant activated factor VII - a new treatment for obstetric haemorrhage?. Anestezjologia Intensywna Terapia. 2003;35:110–112
  16. Pekhlivanov B, Milchev N, Abrashev B. Using recombinant activated coagulation factor VII (NovoSeven®) in obstetrics. Akush Ginekol (Sofiia). 2003;42:7–9
  17. Segal S, Shemesh I, Blumenthal R, et al. Treatment of obstetric haemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynaecol Obstet. 2003;268:266–267
  18. Segal S, Shemesh I, Blumenthal R, et al. The use of recombinant factor VIIa in severe postpartum haemorrhage. Acta Obstet Gynaecol Scand. 2004;83:771–772
  19. Boehlen F, Morales M, Fontana P, Ricou B, Irion O, de Moerloose P. Prolonged treatment of massive post-partum haemorrhage with recombinant factor VIIa: case report and review of the literature. BJOG. 2004;111:284–287
  20. Lim Y, Loo C, Chia V, Fun W. Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy. Int J Gynecol Obstet. 2004;87:178–179
  21. Price G, Kaplan J, Skowronski G. Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a post-partum patient. Br J Anaesth. 2004;93:298–300
  22. Merchant S, Mathew P, Vanderjagt T, Howdieshell T, Crookston K. Recombinant factor VIIa in management of spontaneous subcapsular liver haematoma associated with pregnancy. Obstet Gynecol. 2004;103:1055–1058
  23. Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth. 2005;94:592–595
  24. Holub Z, Feyeresl J, Kabelik L, Rittstein T. Successful treatment of severe post-partum bleeding after caesarean section using recombinant activated factor VII. Ceska Gynecol. 2005;70:144–148
  25. Loudon B, Smith P. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation. Intern Med J. 2005;35:463–467
  26. Martinowitz U, Michaelson M. The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005;3:640–648

PII: S0959-289X(06)00141-5

doi: 10.1016/j.ijoa.2006.07.005

International Journal of Obstetric Anesthesia
Volume 16, Issue 1 , Pages 40-49 , January 2007

Article Tools